ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Sloan-Kettering Cited For 8 Violations Of NY State Standards

November 24, 1995

Breast Density As Important As Age In Determining Risk

September 29, 2006

Breast Cancer Incidence Goes Up, Most of it in Early, Local Stages

July 11, 1988

STI-571 Effects Are Lasting Against GI Stromal Tumors

July 26, 2002

FDA Approves Afinitor For pNET; No Word On Sutent For Same Use

May 6, 2011

NIH Investigation Clear Gallo Of Charge He Stole Aids Virus

October 12, 1990